These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 442204)

  • 21. [Parallels between the development of anemia and hypoglycemia in rats carrying experimental Walker carcinosarcoma 256 and Yoshida sarcoma tumors].
    de la Piedra C; Castro Mendoza HJ
    Rev Clin Esp; 1978 Dec; 151(5):355-7. PubMed ID: 741018
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ultrastructural changes in endothelial cells of blood capillaries of the Walker 256 carcinosarcoma while treated with melatonin].
    Ovsianko EV; Pustovetova MG; Samsonova EN; Ovsianko IaU; Fedina RG; Kulishenko AO; Vinogradov AS
    Vopr Onkol; 2014; 60(2):80-3. PubMed ID: 24919267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of heparin and high molecular dextran (HMD) on tumour metastases].
    Agostino D
    Sangre (Barc); 1976; 21(3):413-20. PubMed ID: 968708
    [No Abstract]   [Full Text] [Related]  

  • 24. [Influence of thymosterine B on the development of Walker carcinosarcoma 256 treated with BCG in rats].
    Potop I; Zimel A
    Endocrinologie; 1980; 18(1):19-21. PubMed ID: 6987725
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of host and tumor calcium in metastases.
    Fisher B; Fisher ER
    Cancer Res; 1968 Sep; 28(9):1753-8. PubMed ID: 5676733
    [No Abstract]   [Full Text] [Related]  

  • 26. Toxicity of intrathecally administered cytotoxic drugs and their antitumor activity against an intrathecal Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat.
    Kooistra KL; Rodriguez M; Powis G
    Cancer Res; 1989 Feb; 49(4):977-82. PubMed ID: 2912564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Metabolic study of sarcoma 45 and Walker carcinosarcoma cells during the process of growth and exposure to anticoagulants (an enzyme cytochemical analysis)].
    Kolomina SM; Pogodina LS; Chentsov IuS; Kudriashov BA; Vasil'eva TN
    Tsitol Genet; 1982; 16(6):18-24. PubMed ID: 7157464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma.
    DeWys WD; Humphreys SR; Goldin A
    Cancer Chemother Rep; 1968 Feb; 52(2):229-42. PubMed ID: 5646850
    [No Abstract]   [Full Text] [Related]  

  • 29. [Some characteristics of the biological action of D, L-1,4-dibromo-1,4-dideoxy-2,3-butanediol].
    Miuller NR; Remizov AL; Belogorodskiĭ VV; Filov VA
    Farmakol Toksikol; 1975; 38(5):590-1. PubMed ID: 1191387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of sodium citrate on the growth of transplantable tumors].
    Prizhivoĭt GN
    Vopr Onkol; 1969; 15(3):77-83. PubMed ID: 5002347
    [No Abstract]   [Full Text] [Related]  

  • 31. [Characteristics of the growth and metastasis of Walker carcinosarcoma following continuous intramuscular passage].
    Shchitkov KF; Bolonina NI; Mandrik EV; Krasner NE
    Vopr Onkol; 1973; 19(3):96-7. PubMed ID: 4762702
    [No Abstract]   [Full Text] [Related]  

  • 32. [Carcinemia and metastasis of Walker carcinosarcoma implanted in the wall of the stomach].
    Sukovatykh LS; Fisher ME; Makkavaeva MIu; Fradkin SZ; Mashevskiĭ AA
    Vopr Onkol; 1970; 16(6):60-3. PubMed ID: 5501581
    [No Abstract]   [Full Text] [Related]  

  • 33. Potentiation by clofibrate of in-vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 carcinosarcoma.
    Gold J
    Cancer Biochem Biophys; 1978; 3(1):41-5. PubMed ID: 552898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Disorders of blood rheology in Walker's carcinosarcoma-256 and in cyclophosphamide treatment of rats].
    Plotnikov MB; Maslov MIu; Aliev OI; Vasil'ev AS; Zueva EP; Krylova SG; Shilova NV
    Vopr Onkol; 2001; 47(3):335-7. PubMed ID: 11544834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of cyclophosphamide and 2,3,5-tris-ethyleniminobenzoquinone-(1,4) on tumor cells in diffusion chambers].
    Teichmann B
    Arzneimittelforschung; 1965 May; 15(5):532-4. PubMed ID: 5898339
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comparative studies of clinically equivalent doses of various cytostatic agents on the mouse Ehrlich ascites carcinoma and rat Walker carcinosarcoma 256 in vivo and in cell culture (in vitro)].
    Matthias M; Tanneberger S; Gummel H
    Arch Geschwulstforsch; 1970; 36(3):240-6. PubMed ID: 5498278
    [No Abstract]   [Full Text] [Related]  

  • 37. Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.
    Keller HJ; Keppler B; Schmähl D
    Arzneimittelforschung; 1982; 32(8):806-7. PubMed ID: 6890355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of guinea-pig serum on the Walker 256 carcinosarcoma.
    Dolowy WC; Schrek R; Henson D; Cornet J; Brown E
    Nature; 1968 Jun; 218(5146):1028-31. PubMed ID: 5656616
    [No Abstract]   [Full Text] [Related]  

  • 39. [Kinetics of the change in free radical content during the development of Walker carcinosarcoma and the action of Thio-TEPA].
    Saprin AN; Minenkova EA; Nagler LG; Kaznacheev IuS; Krugliak SA; Krugliakova KE; Emanuél' NM
    Biofizika; 1967; 12(6):1099-103. PubMed ID: 4318224
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cytogenetic characteristics of Walker carcinosarcoma and its metastases].
    Kiricuta I; Olinici CD
    Vopr Onkol; 1972; 18(3):60-3. PubMed ID: 5017839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.